Treprostinil

A medication used to treat pulmonary arterial hypertension

Treprostinil
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Treprostinil is a medication used in the treatment of pulmonary arterial hypertension (PAH). It is a prostacyclin analogue that works by dilating blood vessels and inhibiting platelet aggregation, thereby reducing blood pressure in the lungs and improving exercise capacity.

Medical uses

Treprostinil is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability. It is administered via several routes, including subcutaneous, intravenous, inhalation, and oral forms. The choice of administration depends on the severity of the condition and patient preference.

Mechanism of action

Treprostinil is a prostacyclin analogue that acts as a vasodilator. It binds to prostacyclin receptors on the surface of vascular smooth muscle cells, leading to increased levels of cyclic adenosine monophosphate (cAMP). This results in relaxation of the smooth muscle cells and vasodilation. Additionally, treprostinil inhibits platelet aggregation, which can help prevent thrombosis in the pulmonary vasculature.

Side effects

Common side effects of treprostinil include headache, diarrhea, nausea, jaw pain, and flushing. More serious side effects can occur, such as bleeding complications, especially in patients taking anticoagulants. Patients receiving the drug via continuous infusion may experience infusion site pain and reactions.

Pharmacokinetics

Treprostinil has a half-life of approximately 4 hours, which allows for continuous infusion or multiple daily dosing. It is metabolized primarily by the liver and excreted in the urine. The pharmacokinetics can vary based on the route of administration.

History

Treprostinil was developed as an alternative to epoprostenol, another prostacyclin analogue, to provide more convenient administration options. It was approved by the United States Food and Drug Administration (FDA) in 2002 for subcutaneous use, with subsequent approvals for other routes of administration.

Related pages

• Pulmonary arterial hypertension
• Prostacyclin
• Vasodilator